Media coverage about Midatech Pharma (NASDAQ:MTP) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Midatech Pharma earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.3067991716339 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Midatech Pharma (MTP) traded up $0.03 during trading on Friday, reaching $1.08. 7,705 shares of the company’s stock traded hands, compared to its average volume of 8,062. Midatech Pharma has a 52-week low of $1.00 and a 52-week high of $3.65. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.49 and a current ratio of 1.62.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-midatech-pharma-mtp-stock-price/1756203.html.

About Midatech Pharma

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Insider Buying and Selling by Quarter for Midatech Pharma (NASDAQ:MTP)

Receive News & Ratings for Midatech Pharma PLC-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC-ADR and related companies with MarketBeat.com's FREE daily email newsletter.